Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders

Nat Rev Drug Discov. 2023 Apr;22(4):273-294. doi: 10.1038/s41573-022-00618-w. Epub 2023 Jan 24.

Abstract

Protein phosphatases act as key regulators of multiple important cellular processes and are attractive therapeutic targets for various diseases. Although extensive effort has been dedicated to phosphatase-targeted drug discovery, early expeditions for competitive phosphatase inhibitors were plagued by druggability issues, leading to the stigmatization of phosphatases as difficult targets. Despite challenges, persistent efforts have led to the identification of several drug-like, non-competitive modulators of some of these enzymes - including SH2 domain-containing protein tyrosine phosphatase 2, protein tyrosine phosphatase 1B, vascular endothelial protein tyrosine phosphatase and protein phosphatase 1 - reigniting interest in therapeutic targeting of phosphatases. Here, we discuss recent progress in phosphatase drug discovery, with emphasis on the development of selective modulators that exhibit biological activity. The roles and regulation of protein phosphatases in immune cells and their potential as powerful targets for immuno-oncology and autoimmunity indications are assessed.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Autoimmune Diseases* / drug therapy
  • Humans
  • Immunotherapy
  • Neoplasms* / drug therapy
  • Phosphoprotein Phosphatases
  • Protein Tyrosine Phosphatases / metabolism

Substances

  • Protein Tyrosine Phosphatases
  • Phosphoprotein Phosphatases